Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on the development of azenosertib (ZN-c3), an investigational oral WEE1 inhibitor designed to treat patients with ovarian cancer and other solid tumors. The company's website is www.zentalis.com.

Zentalis operates as a single-product development company with its primary focus on advancing azenosertib toward regulatory approval and commercialization. The company's lead program targets Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib has demonstrated an objective response rate exceeding 30% in clinical trials with a manageable safety profile. The mechanism of action involves inhibiting WEE1, a DNA damage response kinase, which drives cancer cells into mitosis without adequate DNA repair capability, resulting in cell death and tumor regression.

The company's clinical development strategy includes multiple ongoing trials. DENALI Part 2 is a Phase 2 study in Cyclin E1-positive PROC patients designed to potentially support accelerated FDA approval, with enrollment completed in 2025 and a topline readout anticipated by year-end 2026. ASPENOVA is a planned Phase 3 randomized confirmatory trial comparing azenosertib to standard-of-care chemotherapy, with initiation expected in the first half of 2026. Additionally, the MUIR trial is evaluating azenosertib in combination with bevacizumab as maintenance therapy in ovarian cancer patients.

Zentalis exclusively in-licenses worldwide development and commercialization rights to azenosertib, with key intellectual property licensed from Recurium IP Holdings, LLC. The company holds patent protection for its WEE1 inhibitor program with expected expiration dates between 2038 and 2047, plus potential extensions. The company maintains trademark registrations for ZENTALIS and its associated logo across major markets including the United States, European Union, United Kingdom, Japan, and China.

The company estimates a substantial market opportunity in Cyclin E1-positive PROC, representing approximately 21,500 patients annually in the United States, EU4, and United Kingdom. Zentalis believes azenosertib has broad franchise potential beyond its lead indication across other solid tumor types. The company relies on third-party contract manufacturing organizations for production of azenosertib for clinical and potential commercial use.